Ocean Biomedical, Inc. is a Providence, Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical deploys the funding and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic to the world. Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. The Ocean Biomedical team is working on solving some of the world’s toughest problems, for the people who need it most.
Company profile
Ticker
OCEA, OCEAW
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Aesther Healthcare Acquisition Corp., Ocean Biomedical, Inc./DE
SEC CIK
Corporate docs
IRS number
871309280
OCEA stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
8 Mar 24
8-K
Departure of Directors or Certain Officers
4 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Jan 24
8-K
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
29 Nov 23
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
15 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
8-K
Entry into a Material Definitive Agreement
12 Oct 23
8-K
Ocean Biomedical Announces Loan Commitment from Largest Stockholder; Up to $10 Million
6 Oct 23
8-K
Entry into a Material Definitive Agreement
2 Oct 23
Latest ownership filings
SC 13G
Ayrton Capital LLC
14 Feb 24
SC 13G/A
Lighthouse Investment Partners, LLC
14 Feb 24
SC 13G/A
ATW SPAC MANAGEMENT LLC
13 Feb 24
SC 13G/A
BOOTHBAY FUND MANAGEMENT, LLC
13 Feb 24
SC 13G/A
First Trust Capital Management L.P.
12 Feb 24
SC 13G/A
Polar Asset Management Partners Inc.
9 Feb 24
SC 13G/A
Saba Capital Management, L.P.
7 Feb 24
SC 13G/A
Weiss Asset Management LP
26 Jan 24
4
CHIRINJEEV KATHURIA
6 Oct 23
4
SURENDRA K AJJARAPU
24 Mar 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.16 mm | 1.16 mm | 1.16 mm | 1.16 mm | 1.16 mm | |
Cash burn (monthly) | (no burn) | 893.33 k | 1.96 mm | 1.59 mm | 659.00 k | |
Cash used (since last report) | n/a | 8.00 mm | 17.55 mm | 14.27 mm | 5.90 mm | |
Cash remaining | n/a | -6.83 mm | -16.39 mm | -13.11 mm | -4.74 mm | |
Runway (months of cash) | n/a | -7.7 | -8.4 | -8.2 | -7.2 |
Institutional ownership, Q2 2023
95.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 39 |
Opened positions | 35 |
Closed positions | 21 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 40.35 bn |
Total shares | 32.67 mm |
Total puts | 0.00 |
Total calls | 14.08 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Poseidon Bio | 22.84 mm | $0.00 |
Polar Asset Management Partners | 3.43 mm | $20.57 bn |
Meteora Capital | 1.85 mm | $11.11 bn |
Aesther Healthcare Sponsor | 1.55 mm | $12.39 mm |
Vellar Opportunities Fund Master | 1.52 mm | $0.00 |
BLK Blackrock | 434.98 k | $2.61 bn |
Geode Capital Management | 234.45 k | $1.41 bn |
Quarry | 230.00 k | $1.38 bn |
STT State Street | 122.90 k | $738.65 mm |
Charles Schwab Investment Management | 67.53 k | $405.85 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Oct 23 | Chirinjeev Kathuria | Common Stock, par value $0.0001 | Other | Dispose J | Yes | No | 0 | 500,000 | 0.00 | 22,342,756 |
22 Mar 23 | Ajjarapu Surendra K | Common Stock, par value $0.0001 | Other | Dispose J | Yes | No | 0 | 1,050,000 | 0.00 | 315,000 |
28 Feb 23 | Ajjarapu Surendra K | Common Stock, par value $0.0001 | Other | Acquire J | Yes | No | 0 | 258,200 | 0.00 | 258,200 |
28 Feb 23 | Ajjarapu Surendra K | Common Stock, par value $0.0001 | Other | Acquire J | Yes | No | 0 | 469,300 | 0.00 | 469,300 |
28 Feb 23 | Ajjarapu Surendra K | Other | Dispose J | Yes | No | 0 | 2,625,000 | 0.00 | 1,365,000 | |
28 Feb 23 | Ajjarapu Surendra K | Private Placement Warrant Common Stock | Other | Acquire J | Yes | No | 11.5 | 1,291,000 | 14.85 mm | 1,291,000 |
28 Feb 23 | Ajjarapu Surendra K | Private Placement Warrant Common Stock | Other | Dispose J | Yes | No | 11.5 | 5,411,000 | 62.23 mm | 0 |
28 Feb 23 | Peterson Michael L | Other | Acquire J | No | No | 0 | 80,000 | 0.00 | 80,000 | |
28 Feb 23 | Peterson Michael L | Private Placement Warrant Common Stock | Other | Acquire J | No | No | 11.5 | 200,000 | 2.30 mm | 200,000 |
28 Feb 23 | Ajjarapu Surendra K | Common Stock, par value $0.0001 | Other | Acquire J | Yes | No | 0 | 21,252 | 0.00 | 21,252 |
News
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
7 Mar 24
12 Health Care Stocks Moving In Thursday's Intraday Session
7 Mar 24
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
6 Mar 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
6 Mar 24
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
5 Mar 24
Press releases
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
28 Mar 24
Thinking about buying stock in Marathon Digital, Assertio, Ocean Biomedical, Terns Pharmaceuticals, or NextCure?
12 Mar 24
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?
5 Mar 24
Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting
29 Feb 24
Stocks Making Waves: Insights into Key Developments and Potential VTAK, TBIO, OCEA, ONMD, KZIA
26 Feb 24